NewAmsterdam Pharma Co N.V. Balance Sheet
NAMS / Health Care|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
NewAmsterdam Pharma Co N.V. had $769M in total assets and $683M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $490.0M | $771.7M | $340.4M | - | - |
| Current Assets | $675.7M | $863.4M | $346.8M | $478.0M | - |
| PP&E (Net) | $383.0K | $242.0K | $46.0K | $34.0K | - |
| Total Assets | $769.3M | $864.6M | $347.1M | $478.5M | - |
| Current Liabilities | $85.8M | $106.9M | $49.9M | $36.1M | - |
| Shareholders' Equity | $683.4M | $757.5M | $288.4M | $430.1M | -$113.8M |